{
    "nctId": "NCT00020579",
    "briefTitle": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma",
    "officialTitle": "A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "Dose-limiting toxicities and maximum tolerated dose",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed malignancy that is metastatic or unresectable and for which no effective standard curative or palliative therapy exists\n* Brain metastases allowed provided both of the following criteria are met:\n\n  * Received treatment for the brain metastases\n  * Stable for \u2265 6 months without steroids or antiseizure medications\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nPerformance status:\n\n* ECOG 0-2 OR\n* Karnofsky 50-100%\n\nLife expectancy:\n\n* More than 3 months\n\nHematopoietic:\n\n* WBC at least 3,000/mm\\^3\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN) (\u2264 3 mg/dL for patients with Gilbert's syndrome)\n* AST/ALT no greater than 2.5 times ULN\n* Albumin at least 75% of lower limit of normal\n\nRenal:\n\n* Creatinine normal OR\n* Creatinine clearance at least 60 mL/min\n\nCardiovascular:\n\n* Cardiac ejection fraction normal by MUGA\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia\n\nOther:\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Adequate oral intake\n* No weight loss of more than 10% of actual body weight within the past 2 months\n* No history of allergic reaction to compounds of similar chemical or biological composition to study drug\n* No other uncontrolled illness\n* No ongoing or active infection\n* No seizure disorder\n* No psychiatric illness or social situation that would preclude study compliance\n* No acute or chronic gastrointestinal conditions (e.g., peptic ulcer or colitis) within the past 2 months that would interfere with drug tolerance or absorption\n* Willing and able to self-administer and document doses of MS-275\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* At least 4 weeks since prior anticancer vaccine therapy and recovered\n* No concurrent immunotherapy\n\nChemotherapy:\n\n* At least 4 weeks since prior anticancer chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\n* At least 8 weeks since prior UCN-01 and recovered\n* No concurrent chemotherapy\n\nEndocrine therapy:\n\n* At least 4 weeks since prior anticancer hormonal therapy (except gonadotropin-releasing hormone \\[GnRH\\] agonists) and recovered\n* Concurrent corticosteroids for physiological replacement, as antiemetic therapy, or for an ongoing condition allowed\n\n  * Must be on a stable dose during the past 4 weeks\n* No concurrent anticancer hormonal therapy except GnRH agonists for noncastrated patients with prostate cancer\n\nRadiotherapy:\n\n* At least 4 weeks since prior anticancer radiotherapy and recovered\n* No concurrent radiotherapy\n\n  * Concurrent localized radiotherapy to a single lesion allowed if the patient achieves at least a partial response\n\nSurgery:\n\n* At least 3 weeks since prior major surgery\n\nOther:\n\n* No other concurrent investigational or commercial antineoplastic therapies",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}